^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ecubectedin (PM14)

i
Other names: PM14, PM 14
Associations
Company:
PharmaMar
Drug class:
RNA synthesis inhibitor
Associations
5ms
PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, PharmaMar | Trial completion date: Feb 2023 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Aug 2025
Trial completion date • Trial primary completion date • Metastases
|
BRCA (Breast cancer early onset)
|
ecubectedin (PM14)
over1year
Ecubectedin is a novel transcriptional inhibitor that displays potent antitumor effects in vitro and in vivo (AACR 2023)
Background - Ecubectedin (PM14) is a novel transcriptional inhibitor related to ecteinascidins family...In mice bearing MDA-MB-231, H526 and 22Rv1 tumors, complete tumor remissions were seen in 1/10 (lasting 103 days), 9/10 (lasting 220 days) and 7/10 (lasting 13 days) ecubectedin-treated animals, respectively.Conclusions - Ecubectedin is a novel transcriptional inhibitor that displays potent antiproliferative activity in different human solid cancer models in vitro and in vivo. The drug is currently in clinical development in Phase II trials.
Preclinical
|
TNFA (Tumor Necrosis Factor-Alpha) • ANXA5 (Annexin A5)
|
ecubectedin (PM14)
over2years
PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, PharmaMar | Active, not recruiting --> Recruiting
Enrollment open
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
ecubectedin (PM14)
3years
PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=150, Active, not recruiting, PharmaMar | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
ecubectedin (PM14)
3years
Clinical • New P1 trial
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
ecubectedin (PM14)